Loading…
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $256M | $-161M | $-103M | $12M | -28.4% | 23.3% | -44.8% |
| 2024 | $208M | $-203M | $-187M | $-165M | -44.4% | -4.2% | -559.5% |
| 2023 | $217M | $-172M | $41M | $-150M | 7.4% | 19.7% | -127.3% |
| 2022 | $181M | $-142M | $-149M | $-128M | -33.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 180.96 | 216.67 | 207.54 | 255.87 |
| Cost Of Revenue | - | 79.93 | 75.97 | 75.46 | 113.26 |
| Gross Profit | - | 101.02 | 140.69 | 132.08 | 142.61 |
| Operating Expense | - | 247.84 | 318.14 | 341.38 | 309.51 |
| Operating Income | - | -146.82 | -177.45 | -209.30 | -166.90 |
| EBITDA | - | -142.47 | -171.90 | -203.14 | -160.87 |
| EBIT | - | -146.82 | -177.45 | -209.30 | -166.90 |
| Pretax Income | - | -149.12 | 42.92 | -185.71 | -102.33 |
| Tax Provision | - | 0.06 | 2.20 | 1.41 | 0.94 |
| Net Income | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Net Income Common Stockholders | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Total Expenses | - | 327.77 | 394.11 | 416.84 | 422.76 |
| Interest Income | 1.06 | - | - | - | - |
| Research And Development | - | 126.37 | 181.77 | 201.78 | 173.14 |
| Selling General And Administration | - | 121.47 | 136.37 | 139.59 | 136.37 |
| Normalized EBITDA | - | -124.39 | -225.36 | -208.82 | -209.05 |
| Normalized Income | - | -134.90 | -10.01 | -191.61 | -141.32 |
| Market Cap | 870.40 | 870.40 | 870.40 | 870.40 | 870.40 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Schrödinger, Inc.this co. | SDGR | - | -8.43 | 2.39 | -28.4% | -4.66 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - |
| - |
| - |
| - |
| - |
| - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |